Cybin Inc. (CYBN)
| Bid | 5.9 |
| Market Cap | 117.31M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -3.47 |
| PE Ratio (ttm) | -1.72 |
| Forward PE | -1.65 |
| Analyst | Buy |
| Ask | 6.45 |
| Volume | 167,376 |
| Avg. Volume (20D) | 264,875 |
| Open | 6.00 |
| Previous Close | 6.26 |
| Day's Range | 5.91 - 6.20 |
| 52-Week Range | 5.73 - 17.48 |
| Beta | 1.09 |
About CYBN
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company...
Analyst Forecast
According to 4 analyst ratings, the average rating for CYBN stock is "Buy." The 12-month stock price forecast is $73, which is an increase of 1124.83% from the latest price.
Stock Forecasts
2 months ago · businesswire.com
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcar...
